Scarica l'app Stockscreener
1.36
3.55%
-0.05
Dopo l'orario di chiusura:
1.41
0.05
+3.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.41
Aprire:
$1.41
Volume 24 ore:
605.26K
Relative Volume:
0.53
Capitalizzazione di mercato:
$96.16M
Reddito:
-
Utile/perdita netta:
$-95.71M
Rapporto P/E:
-0.5687
EPS:
-2.3915
Flusso di cassa netto:
$-87.27M
1 W Prestazione:
-2.16%
1M Prestazione:
+8.80%
6M Prestazione:
-29.53%
1 anno Prestazione:
-48.87%
Intervallo 1D:
$1.335
$1.445
Intervallo di 1 settimana:
$1.325
$1.59
Portata 52W:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.36 | 96.16M | 0 | -95.71M | -87.27M | -2.3915 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 - GlobeNewswire
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - Yahoo Finance
Aug Fed Impact: Can Biomea Fusion Inc sustain its profitabilityMarket Movers & Risk Managed Investment Entry Signals - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biomea Fusion to present icovamenib clinical data at ATTD 2006 - Traders Union
Icovamenib advances drive optimism for diabetes cure, Biomea Fusion asserts - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
BMEA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Biomea Fusion, Inc. (BMEA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Aug Spikes: Can Biomea Fusion Inc ride the EV waveWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - MarketBeat
BMEA: Icovamenib and BMF-650 advance in trials, targeting unmet needs in diabetes and weight loss - TradingView
Biomea Fusion : 1ST QUARTER 2026 Corporate Presentation OPCO - marketscreener.com
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline - TipRanks
Biomea Fusion posts updated investor presentation, confirms Phase II readouts and Phase I obesity data timing - TradingView
Biomea Fusion (NASDAQ: BMEA) details icovamenib and BMF-650 trial milestones - Stock Titan
Does Biomea Fusion Inc. stock trade at a discount to peersOptions Play & Momentum Based Trading Signals - mfd.ru
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Biomea Fusion advances metabolic disease science with visionary approach - Traders Union
7.85M Biomea Fusion (BMEA) shares reported in 9.9% ownership filing - Stock Titan
BMEA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Biomea Fusion Inc. sustain its profitabilityMarket Risk Analysis & Smart Money Movement Tracker - mfd.ru
How Biomea Fusion Inc. stock reacts to job market dataWeekly Earnings Recap & Proven Capital Preservation Methods - mfd.ru
Can Biomea Fusion Inc. ride the EV waveJuly 2025 Trade Ideas & Reliable Trade Execution Plans - mfd.ru
BMEA Should I Buy - Intellectia AI
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Biomea Fusion Inc. stock appeals to analysts2025 Geopolitical Influence & Smart Swing Trading Techniques - mfd.ru
BMEA PE Ratio & Valuation, Is BMEA Overvalued - Intellectia AI
Why Biomea Fusion Inc. stock is recommended by analystsJuly 2025 WrapUp & Consistent Profit Trade Alerts - mfd.ru
Biomea Fusion (NASDAQ:BMEA) Shares Down 3%What's Next? - MarketBeat
Is Biomea Fusion Inc. stock a falling knife or bargain buy2025 Big Picture & Proven Capital Preservation Methods - mfd.ru
Biomea Fusion signals risk of beta cell overwork in diabetes - Traders Union
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know - MSN
Does Biomea Fusion Inc stock benefit from AI growth2025 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Market Catalysts: Is Biomea Fusion Inc part of any major indexJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance
Levels Update: Does Biomea Fusion Inc offer margin of safetyQuarterly Performance Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Insider Monkey
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones - MarketBeat
BMEA: Durable A1C reduction and advancing weight loss studies highlight strong clinical momentum - TradingView
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference - TipRanks
Biomea Fusion, Inc. Updates on Icovamenib Clinical Progress - TradingView
Rodman & Renshaw Initiates Coverage on Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Rodman & Renshaw initiates Biomea Fusion stock with Buy rating By Investing.com - Investing.com Nigeria
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):